

Orthocell Board Changes

- Following the appointment of the Hon Kim Beazley AC, former Australian US Ambassador and Governor of Western Australia, Mr Matthew Callahan has retired from the Board.
- Mr Callahan has served as a valued member of the Board since 2006 and has greatly assisted with the successful commercialisation the Company's initial products.
- With an experienced senior, multinational advisory team and an advanced regenerative medicine portfolio, Orthocell is ideally positioned to drive its products into the global markets.

Perth, Australia; 15 January 2024: Regenerative medicine company Orthocell Limited (ASX:OCC, "Orthocell" or the "Company") today announced that as part of its Board renewal program and following the appointment of the Hon Kim Beazley AC to the Board, , Mr Matthew Callahan, has resigned from the Board.

Orthocell Chairman, Mr John Van Der Wielen, said: *"Matt's commitment and contributions to the success of Orthocell in the early phase of the Company and as it transitioned from an R&D company to a commercial success is commendable and greatly appreciated. Matt was pivotal to the initial public offer and greatly assisted the Company through first-in-human trials and successful commercialisation of our initial products in international markets. I sincerely wish Matt all the best in his future endeavours."*

The appointment of Mr Beazley is part of an exciting chapter of new leadership at the Board level, as Orthocell executes its global commercialisation and revenue growth plan for its world-class regenerative medicine product portfolio. This news follows the recent appointment of experienced Chairman, Mr John Van Der Wielen, and another highly credentialed Independent Non-Executive Director, Professor Fiona Wood AM.

Following Kim's appointment and the resignation of Matthew Callahan, the Orthocell Board has five Directors comprising four Non-Executive Directors and one Executive Director. With an experienced Board and Management Team, market leading products and strong balance sheet, Orthocell is well positioned to grow product sales alongside its distribution partners, BioHorizons and Device Technologies – which includes, as a priority, executing its US market access program and commercialisation strategy for its breakthrough nerve repair medical device, Remplir™.

The aforementioned Board change is effective from 5.00 pm, 15 January 2024.

Release authorised by Managing Director Orthocell Ltd, Paul Anderson.

For more information, please contact:

General & Investor enquiries

Paul Anderson
Orthocell Limited
Managing Director

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
HACK Director

P: +61 423 139 163

E: haley@hck.digital

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include CelGro™ platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer, manufacturing scale up and FDA engagement in advance of a randomised controlled study under FDA supervision.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.